IGC Pharma (IGC) said Tuesday it is expanding its phase 2 trial of IGC-AD1 in Alzheimer's disease by adding Butler Hospital's Memory and Aging Program in Providence, Rhode Island.
The site will help enroll participants for the study of IGC-AD1
potential in reducing agitation in Alzheimer's dementia, the company said. The research center is affiliated with the Warren Alpert Medical School of Brown University.
The trial is being conducted in the US and Canada, with a goal of enrolling 146 participants, IGC said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.